Silexion Therapeutics Bolsa (NASDAQ: SLXN)

Últimas noticias sobre Silexion Therapeutics (NASDAQ:SLXN) Bolsa

Silexion Therapeutics

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Lattice Semiconductor sorprende con un alza del 14,7% en el premercado. Descubre qué otras acciones están en movimiento.

Acciones de Lattice Semiconductor (LSCC) suben un 15%; 20 acciones que se mueven en el premercado

APPS

AVGR

BBAI

COHR

DGLY

FORM

MBRX

MTRX

PTIX

RANI

RXRX

SBET

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SWKS

Coherent sorprende con sus resultados trimestrales y dispara sus acciones un 15,5%. ¿Qué otras empresas se mueven en el premercado de EE.UU.?

Acciones de Coherent (COHR) se disparan un 15%; 20 acciones que se mueven en el premercado de EE.UU.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

ANTA

Antalpha Platform Shares Halted On Circuit Breaker To The Upside At $16.51/Share

RBC Capital analyst Brian Abrahams reiterates Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) with a Sector Perform and maintains $1.5 price target.

Price Target

Reiteration

Analyst Ratings

APLT

RBC Capital Reiterates Sector Perform on Applied Therapeutics, Maintains $1.5 Price Target

Solana (SOL) climbed <a href="https://www.benzinga.com/money/how-to-buy-solana#:~:text=Make%20Your%20Purchase&amp;text=To%20complete%20the%20transaction%2C%20head,you%20would%20like%20to%20purchase.">6.2% over 24 hours to $181.54</a>, outpacing the broader crypto market&#8217;s 12.7% uptick this week. The push leaves SOL up 23.4% on the week, and 37.14% over the past month, according to CoinMarketCap.
The surge comes on the heel of the U.S. Securities and Exchange Commission&#8217;s (SEC) delay of its decision on Grayscale&#8217;s proposed Solana ETF, signaling renewed bullish momentum in the wake of improving on‑chain fundamentals, ecosystem growth, and growing investor appetite.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
According to BeInCrypto, the SEC&#8217;s filing emphasized that the deferral &#8220;does not indicate any conclusions&#8221; and invited public comment on the proposed rule change—muting immediate price fallout as analysts expect approval later this year.
Meanwhile, big players are quietly stacking up their SOL stashes. Nasdaq‑listed DeFi Development Corp. announced that it added 172,670 SOL (about $23.6 million at an average $136.81 price) to its treasury, bringing its total holdings to nearly 595,000 SOL (worth $102.7 million). It&#8217;s the firm&#8217;s largest single acquisition to date, a concrete vote of confidence in Solana&#8217;s long‑term scalability and yield potential.
On the retail front, Solana&#8217;s meme‑coin scene is back in the spotlight. According to Decrypt, a trader turned a modest $332 wager on Gooncoin (a Solana‑based meme token) into $190,000 in a matter of days. It&#8217;s an extreme example, but it highlights how Solana&#8217;s low fees and fast block times have reignited speculative fervor. This also highlights how hype and liquidity are converging to fuel outsized short‑term returns within Solana&#8217;s fringe markets.
Digging deeper, the network&#8217;s health metrics underscore that this isn&#8217;t just hype. CoinMarketCap found that the daily active addresses are approaching multi‑month highs. Meanwhile, total value locked (TVL) in Solana‑based DeFi protocols continues to climb, exceeding that of all Ethereum layer 2s combined, a sign that genuine user adoption is underpinning the price moves, not just thrill‑seeking traders.
Solana isn&#8217;t stopping there. According to BitcoinInfoNews.com, the network is forging new speed‑optimized partnerships to bolster on‑chain payments, enabling fast, low‑cost transactions at scale. These alliances position SOL as more than a DeFi play, and usher it into real‑world use cases in micropayments and tokenized commerce.
Looking ahead, keep an eye on the $185 level as the next resistance hurdle. A sustained break above it could send SOL toward the $200 to $220 zone, while failure to hold current gains may trigger a dip back to the $172 to $175 range. The ultimate catalyst may be an eventual green light for a Solana ETF, and upcoming protocol upgrades, such as improvements to cross‑chain bridges and smart‑contract tooling.
Solana&#8217;s price action splashed with vibrant retail activity, institutional endorsements in the background, and a quietly strengthening network infrastructure, paints a compelling picture. While regulatory roadblocks may slow the pace, the pieces are falling into place for a bullish second half of 2025.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Solana Price Jumps 6% amid ETF delay and meme-coin mania

WIIM

HYPR

Hyperfine shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 sales guidance below estimates. Also, Wells Fargo maintained an Equal-Weight rating on the stock and lowered its price target from $1.29 to $0.68.

IPOs

Antalpha Platform IPO Opens For Trade At $15.01/Share; IPO Priced At $12.80/Share On 3.85M Shares

Goldman Sachs analyst John Mackay maintains Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy and lowers the price target from $20 to $17.5.

Goldman Sachs Maintains Buy on Venture Global, Lowers Price Target to $17.5

ELMD

Electromed shares are trading lower after the company reported worse-than-expected Q3 sales results.

VRCA

Verrica Pharmaceuticals shares are trading lower. The company reported Q1 financial results.

Goldman Sachs analyst Caitlin Burrows maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Buy and lowers the price target from $28 to $25.

SAFE

Goldman Sachs Maintains Buy on Safehold, Lowers Price Target to $25

LXRX

Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.

Goldman Sachs analyst Eric Sheridan maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Neutral and raises the price target from $63 to $80.

RBLX

Goldman Sachs Maintains Neutral on Roblox, Raises Price Target to $80

SLND

Southland Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) with a Outperform and maintains $10 price target.

ALLO

RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Overweight and lowers the price target from $9 to $5.

SGMO

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Goldman Sachs analyst Will Nance maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and raises the price target from $56 to $64.

HOOD

Goldman Sachs Maintains Buy on Robinhood Markets, Raises Price Target to $64

Protagenic Therapeutics shares are trading lower. The company reported Q1 financial results.

WATT

Energous shares are trading lower. The company reported Q1 financial results.

Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) with a Buy and lowers the price target from $20 to $18.

OLMA

Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $18

ANEB

Anebulo Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 EPS results.

Goldman Sachs analyst Irma Sgarz maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Buy and raises the price target from $2640 to $3000.

MELI

Goldman Sachs Maintains Buy on MercadoLibre, Raises Price Target to $3000

Health Care

Press Releases

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Collaborates with Multi Billion Dollar Clinical Development Player, Advancing Revolutionary Cancer Treatment Toward Clinical Trials

Earnings

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Comments

Silexion Therapeutics

Noticias

Últimas noticias sobre Silexion Therapeutics (NASDAQ:SLXN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL